Julian Baker Baker Bros. Advisors
Julian Baker is co-managing member of Baker Bros. Advisors, a firm renowned for deep specialization in biotechnology and life sciences. The firm is known for concentrated positions, long holding periods, and scientific diligence that goes well beyond typical generalist research. Baker Bros. filings are closely watched by healthcare investors for signals in clinical-stage and commercial biotech.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Roivant Sciences
ROIV
|
+$27.7M |
| 2 |
AbCellera Biologics
ABCL
|
+$26.2M |
| 3 |
Ultragenyx Pharmaceutical
RARE
|
+$23.1M |
| 4 |
Denali Therapeutics
DNLI
|
+$21.2M |
| 5 |
Monte Rosa Therapeutics
GLUE
|
+$12.2M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
argenx
ARGX
|
+$63.1M |
| 2 |
KDNY
Chinook Therapeutics, Inc. Common Stock
KDNY
|
+$55.9M |
| 3 |
DICE
DICE Therapeutics, Inc. Common Stock
DICE
|
+$48.1M |
| 4 |
IMGN
Immunogen Inc
IMGN
|
+$28.7M |
| 5 |
AnaptysBio
ANAB
|
+$12.8M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 99.2% |
| 2 | Financials | 0.01% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
51
Taysha Gene Therapies
TSHA
$1.98B
| $7.92M | 0.05% |
+2,504,756
| New | +$4.68M |
|
52
Sana Biotechnology
SANA
$1.17B
| $7.74M | 0.04% |
2,000,000
| – | – |
|
|
BLUE
53
DELISTED
bluebird bio
BLUE
| $7.6M | 0.04% |
124,986
| – | – |
|
54
ARS Pharmaceuticals
SPRY
$547M
| $7.58M | 0.04% |
2,006,451
| – | – |
|
55
Sagimet Biosciences
SGMT
$637M
| $7.18M | 0.04% |
+815,359
| New | +$10.9M |
|
56
TScan Therapeutics
TCRX
$52.8M
| $7.13M | 0.04% |
2,784,792
| – | – |
|
57
Geron
GERN
$977M
| $6.49M | 0.04% |
3,061,224
| – | – |
|
|
LONA
58
LeonaBio Inc
LONA
$72.4M
| $6.37M | 0.04% |
315,381
| – | – |
|
59
Alector
ALEC
$264M
| $6.25M | 0.04% |
964,851
| – | – |
|
60
Mirum Pharmaceuticals
MIRM
$5.87B
| $6.02M | 0.03% |
+190,476
| New | +$5.22M |
|
61
Edgewise Therapeutics
EWTX
$4.8B
| $6.01M | 0.03% |
1,049,699
+549,699
| +110% | +$3.74M |
|
62
Summit Therapeutics
SMMT
$10.5B
| $5.87M | 0.03% |
3,140,473
-3,164,232
| -50% | -$6.03M |
|
63
Stoke Therapeutics
STOK
$2.08B
| $5.85M | 0.03% |
1,485,915
-644,323
| -30% | -$4.24M |
|
|
HOOK
64
DELISTED
HOOKIPA Pharma
HOOK
| $4.97M | 0.03% |
806,540
+363,986
| +82% | +$2.67M |
|
|
MORF
65
DELISTED
Morphic Holding, Inc. Common Stock
MORF
| $4.94M | 0.03% |
+215,800
| New | +$11.3M |
|
66
Celcuity
CELC
$4.58B
| $4.89M | 0.03% |
+535,478
| New | +$5.27M |
|
67
Neurogene
NGNE
$773M
| $4.82M | 0.03% |
305,354
+114,267
| +60% | +$1.69M |
|
|
WHWK
68
Whitehawk Therapeutics
WHWK
$270M
| $4.79M | 0.03% |
989,928
| – | – |
|
|
OPT
69
DELISTED
Opthea Limited American Depositary Shares
OPT
| $4.69M | 0.03% |
2,690,891
-500
| -0% | -$1.33K |
|
70
Natera
NTRA
$47.9B
| $4.42M | 0.03% |
100,000
| – | – |
|
71
Design Therapeutics
DSGN
$938M
| $3.54M | 0.02% |
1,500,000
+1,000,000
| +200% | +$4.66M |
|
72
Praxis Precision Medicines
PRAX
$10.5B
| $3.21M | 0.02% |
125,328
| – | – |
|
73
Compass Therapeutics
CMPX
$432M
| $3.07M | 0.02% |
1,557,630
| – | – |
|
|
TLIS
74
DELISTED
Talis Biomedical Corporation Common Stock
TLIS
| $2.93M | 0.02% |
508,323
+1
| +0% | +$7 |
|
|
GRCL
75
DELISTED
Gracell Biotechnologies Inc. American Depositary Shares
GRCL
| $2.88M | 0.02% |
1,000,000
| – | – |
|
Similar funds
Julian Baker's Q3 2023 Portfolio in Review
As of Q3 2023, Julian Baker held 115 positions worth $17.4B, up 0.42% from $17.3B the previous quarter. Its ten largest holdings account for 90% of the portfolio.
Julian Baker's Q3 2023 filing shows 7 new, 18 increased, 11 reduced and 14 closed positions. Its largest new stake was Morphic Holding, Inc. Common Stock: 215,800 shares worth $4.94M. The largest sale was argenx, an estimated $63.1M.
By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 99% a quarter earlier, followed by Financials.
- Julian Baker's largest Q3 2023 buy was Morphic Holding, Inc. Common Stock: 215,800 shares worth $4.94M.
- Julian Baker added most to Roivant Sciences in Q3 2023, an estimated $27.7M increase.
- Julian Baker's biggest Q3 2023 reduction was argenx, cutting an estimated $63.1M.
- Julian Baker fully exited Chinook Therapeutics, Inc. Common Stock in Q3 2023, selling an estimated $55.9M.
- Julian Baker's ten largest holdings make up 90% of its $17.4B portfolio in Q3 2023.
- Julian Baker opened 7 new positions and closed 14 in Q3 2023.
- Julian Baker's portfolio value rose 0.42% quarter-over-quarter to $17.4B.
Based on Baker Bros. Advisors's 13F filing for Q3 2023, filed 14 Nov 2023.